Conference Coverage

Certolizumab Eased Skin and Joint Symptoms in PsA


 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Mease reported financial relation ships with UCB, which markets certolizumab. In addition, as a clinical trialist he has financial relationships with numerous other pharmaceutical companies that are interested in rheumatologic diseases.

Pages

Recommended Reading

Rethinking the Pathogenesis of Psoriatic Arthritis
Psoriasis Collection
Lung Infections More Common Among Anti-TNF Users
Psoriasis Collection
HIV Infection Complicates Rheumatologic Treatments and Vice Versa
Psoriasis Collection
Panel Recommends Tofacitinib Approval for Refractory RA
Psoriasis Collection
Biologics for RA Do Not Increase Solid Cancer Risk
Psoriasis Collection
Avoid Certain Vaccine-Biologic Combos
Psoriasis Collection
Smokers Less Likely to Respond to Biologic Treatment for RA
Psoriasis Collection
Could a Urine Test Predict Response to Biologics?
Psoriasis Collection
High-Dose Ustekinumab Stomps Out Palmoplantar Psoriasis
Psoriasis Collection
Weight Contributes to Anti-TNF Response in PsA
Psoriasis Collection